The current PE ratio of LFCR cannot be calculated, as the latest EPS of -$1.48 is negative. Lifecore Biomedical's last PE ratio on record was 27.27 in August 2024.
The mean historical PE ratio of Lifecore Biomedical over the last ten years is 88.37. Looking back at the last ten years, LFCR's PE ratio peaked in the May 2019 quarter at 942, with a price of $9.42 and an EPS of $0.01. The May 2024 quarter marked the lowest point at 14.05, with a price of $5.62 and an EPS of $0.4.
Maximum annual increase: 5,934.59% in 2019
Maximum annual decrease: -62.88% in 2012
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
2024 | 14.05 | N/A | $5.62 | $0.4 |
2023 | N/A | N/A | $7.94 | -$3.32 |
2022 | N/A | N/A | $9.87 | -$3.97 |
2021 | N/A | N/A | $11.97 | -$1.1 |
2020 | N/A | N/A | $10.67 | -$1.31 |
2019 | 942 | 5,934.59% | $9.42 | $0.01 |
2018 | 15.61 | -55.4% | $14.05 | $0.9 |
2017 | 35 | N/A | $13.65 | $0.39 |
2016 | N/A | N/A | $11.46 | -$0.43 |
2015 | 28.58 | 71.34% | $14.29 | $0.5 |
2014 | 16.68 | 4.58% | $12.01 | $0.72 |
2013 | 15.95 | 10.53% | $13.88 | $0.87 |
2012 | 14.43 | -62.88% | $7.07 | $0.49 |
2011 | 38.87 | -5.82% | $5.83 | $0.15 |
2010 | 41.27 | 82.61% | $6.19 | $0.15 |
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
Feb 2025 | N/A | N/A | $5.61 | -$1.48 |
Nov 2024 | N/A | N/A | $7.31 | -$0.5 |
Aug 2024 | 27.27 | 94.09% | $6 | $0.22 |
May 2024 | 14.05 | N/A | $5.62 | $0.4 |
Feb 2024 | N/A | N/A | $8.07 | -$0.67 |
Nov 2023 | N/A | N/A | $7.51 | -$2.38 |
Aug 2023 | N/A | N/A | $8.39 | -$3.28 |
May 2023 | N/A | N/A | $7.94 | -$3.32 |
Feb 2023 | N/A | N/A | $5.85 | -$3.9 |
Nov 2022 | N/A | N/A | $8.37 | -$3.15 |
Aug 2022 | N/A | N/A | $10.19 | -$4.02 |
May 2022 | N/A | N/A | $9.87 | -$3.97 |
Feb 2022 | N/A | N/A | $11.54 | -$2.87 |
Nov 2021 | N/A | N/A | $8.67 | -$2.47 |
Aug 2021 | N/A | N/A | $10.87 | -$1.62 |
Stock name | PE ratio | Market cap |
---|---|---|
OPTN OptiNose Inc | N/A | $91.66M |
OPK Opko Health Inc | N/A | $1.04B |
ORGO Organogenesis Holdings Inc | N/A | $490.82M |
LFCR Lifecore Biomedical Inc | N/A | $195.86M |
The current price to earnings ratio of LFCR cannot be determined, as its EPS of -$1.48 is negative.
The highest quarterly PE ratio in the last ten years has been 942 and it was in the May 2019 quarter.
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from and Sharadar.